Global Microbiome Therapeutics Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
Summary
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
According to APO Research, The global Microbiome Therapeutics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Microbiome Therapeutics include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma and Second Genome, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Microbiome Therapeutics, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Microbiome Therapeutics, also provides the value of main regions and countries. Of the upcoming market potential for Microbiome Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Microbiome Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Microbiome Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Microbiome Therapeutics company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Microbiome Therapeutics segment by Company
1. To analyze and research the global Microbiome Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Microbiome Therapeutics key companies, revenue, market share, and recent developments.
3. To split the Microbiome Therapeutics breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Microbiome Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Microbiome Therapeutics significant trends, drivers, influence factors in global and regions.
6. To analyze Microbiome Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Microbiome Therapeutics industry.
Chapter 3: Detailed analysis of Microbiome Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Microbiome Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Microbiome Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
According to APO Research, The global Microbiome Therapeutics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Microbiome Therapeutics include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma and Second Genome, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Microbiome Therapeutics, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Microbiome Therapeutics, also provides the value of main regions and countries. Of the upcoming market potential for Microbiome Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Microbiome Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Microbiome Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Microbiome Therapeutics company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Microbiome Therapeutics segment by Company
- Seres Therapeutics
- Assembly Biosciences
- Synthetic Biologics
- Interxon
- PureTech
- Synlogic
- Enterome BioScience
- 4D Pharma
- Second Genome
- AOBiome
- C3 Jian
- Rebiotix
- MicroBiome Therapeutics LLC
- Metabiomics
- Ritter Pharmaceuticals
- Symberix
- OpenBiome
- Azitra
- Symbiotix Biotherapies
- Osel
- Metabogen
- Upper GIT
- Lower GIT
- C. difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Orphan Drug
- Immuno-oncology
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global Microbiome Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Microbiome Therapeutics key companies, revenue, market share, and recent developments.
3. To split the Microbiome Therapeutics breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Microbiome Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Microbiome Therapeutics significant trends, drivers, influence factors in global and regions.
6. To analyze Microbiome Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Microbiome Therapeutics industry.
Chapter 3: Detailed analysis of Microbiome Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Microbiome Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Microbiome Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Microbiome Therapeutics Market Size, 2019 VS 2023 VS 2030
1.3 Global Microbiome Therapeutics Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 MICROBIOME THERAPEUTICS MARKET DYNAMICS
2.1 Microbiome Therapeutics Industry Trends
2.2 Microbiome Therapeutics Industry Drivers
2.3 Microbiome Therapeutics Industry Opportunities and Challenges
2.4 Microbiome Therapeutics Industry Restraints
3 MICROBIOME THERAPEUTICS MARKET BY COMPANY
3.1 Global Microbiome Therapeutics Company Revenue Ranking in 2023
3.2 Global Microbiome Therapeutics Revenue by Company (2019-2024)
3.3 Global Microbiome Therapeutics Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Microbiome Therapeutics Company Manufacturing Base & Headquarters
3.5 Global Microbiome Therapeutics Company, Product Type & Application
3.6 Global Microbiome Therapeutics Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Microbiome Therapeutics Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Microbiome Therapeutics Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 MICROBIOME THERAPEUTICS MARKET BY TYPE
4.1 Microbiome Therapeutics Type Introduction
4.1.1 Upper GIT
4.1.2 Lower GIT
4.2 Global Microbiome Therapeutics Sales Value by Type
4.2.1 Global Microbiome Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Microbiome Therapeutics Sales Value by Type (2019-2030)
4.2.3 Global Microbiome Therapeutics Sales Value Share by Type (2019-2030)
5 MICROBIOME THERAPEUTICS MARKET BY APPLICATION
5.1 Microbiome Therapeutics Application Introduction
5.1.1 C. difficile Infection (CDI)
5.1.2 Inflammatory Bowel Disease (IBD)
5.1.3 Orphan Drug
5.1.4 Immuno-oncology
5.1.5 Others
5.2 Global Microbiome Therapeutics Sales Value by Application
5.2.1 Global Microbiome Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Microbiome Therapeutics Sales Value by Application (2019-2030)
5.2.3 Global Microbiome Therapeutics Sales Value Share by Application (2019-2030)
6 MICROBIOME THERAPEUTICS MARKET BY REGION
6.1 Global Microbiome Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Microbiome Therapeutics Sales Value by Region (2019-2030)
6.2.1 Global Microbiome Therapeutics Sales Value by Region: 2019-2024
6.2.2 Global Microbiome Therapeutics Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Microbiome Therapeutics Sales Value (2019-2030)
6.3.2 North America Microbiome Therapeutics Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Microbiome Therapeutics Sales Value (2019-2030)
6.4.2 Europe Microbiome Therapeutics Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Microbiome Therapeutics Sales Value (2019-2030)
6.5.2 Asia-Pacific Microbiome Therapeutics Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Microbiome Therapeutics Sales Value (2019-2030)
6.6.2 Latin America Microbiome Therapeutics Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Microbiome Therapeutics Sales Value (2019-2030)
6.7.2 Middle East & Africa Microbiome Therapeutics Sales Value Share by Country, 2023 VS 2030
7 MICROBIOME THERAPEUTICS MARKET BY COUNTRY
7.1 Global Microbiome Therapeutics Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Microbiome Therapeutics Sales Value by Country (2019-2030)
7.2.1 Global Microbiome Therapeutics Sales Value by Country (2019-2024)
7.2.2 Global Microbiome Therapeutics Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.3.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.4.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.5.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.6.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.7.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.8.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.9.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.10.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.11.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.12.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.13.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.14.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.15.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.16.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.17.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.18.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.19.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.20.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.21.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Seres Therapeutics
8.1.1 Seres Therapeutics Comapny Information
8.1.2 Seres Therapeutics Business Overview
8.1.3 Seres Therapeutics Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.1.4 Seres Therapeutics Microbiome Therapeutics Product Portfolio
8.1.5 Seres Therapeutics Recent Developments
8.2 Assembly Biosciences
8.2.1 Assembly Biosciences Comapny Information
8.2.2 Assembly Biosciences Business Overview
8.2.3 Assembly Biosciences Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.2.4 Assembly Biosciences Microbiome Therapeutics Product Portfolio
8.2.5 Assembly Biosciences Recent Developments
8.3 Synthetic Biologics
8.3.1 Synthetic Biologics Comapny Information
8.3.2 Synthetic Biologics Business Overview
8.3.3 Synthetic Biologics Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.3.4 Synthetic Biologics Microbiome Therapeutics Product Portfolio
8.3.5 Synthetic Biologics Recent Developments
8.4 Interxon
8.4.1 Interxon Comapny Information
8.4.2 Interxon Business Overview
8.4.3 Interxon Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.4.4 Interxon Microbiome Therapeutics Product Portfolio
8.4.5 Interxon Recent Developments
8.5 PureTech
8.5.1 PureTech Comapny Information
8.5.2 PureTech Business Overview
8.5.3 PureTech Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.5.4 PureTech Microbiome Therapeutics Product Portfolio
8.5.5 PureTech Recent Developments
8.6 Synlogic
8.6.1 Synlogic Comapny Information
8.6.2 Synlogic Business Overview
8.6.3 Synlogic Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.6.4 Synlogic Microbiome Therapeutics Product Portfolio
8.6.5 Synlogic Recent Developments
8.7 Enterome BioScience
8.7.1 Enterome BioScience Comapny Information
8.7.2 Enterome BioScience Business Overview
8.7.3 Enterome BioScience Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.7.4 Enterome BioScience Microbiome Therapeutics Product Portfolio
8.7.5 Enterome BioScience Recent Developments
8.8 4D Pharma
8.8.1 4D Pharma Comapny Information
8.8.2 4D Pharma Business Overview
8.8.3 4D Pharma Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.8.4 4D Pharma Microbiome Therapeutics Product Portfolio
8.8.5 4D Pharma Recent Developments
8.9 Second Genome
8.9.1 Second Genome Comapny Information
8.9.2 Second Genome Business Overview
8.9.3 Second Genome Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.9.4 Second Genome Microbiome Therapeutics Product Portfolio
8.9.5 Second Genome Recent Developments
8.10 AOBiome
8.10.1 AOBiome Comapny Information
8.10.2 AOBiome Business Overview
8.10.3 AOBiome Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.10.4 AOBiome Microbiome Therapeutics Product Portfolio
8.10.5 AOBiome Recent Developments
8.11 C3 Jian
8.11.1 C3 Jian Comapny Information
8.11.2 C3 Jian Business Overview
8.11.3 C3 Jian Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.11.4 C3 Jian Microbiome Therapeutics Product Portfolio
8.11.5 C3 Jian Recent Developments
8.12 Rebiotix
8.12.1 Rebiotix Comapny Information
8.12.2 Rebiotix Business Overview
8.12.3 Rebiotix Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.12.4 Rebiotix Microbiome Therapeutics Product Portfolio
8.12.5 Rebiotix Recent Developments
8.13 MicroBiome Therapeutics LLC
8.13.1 MicroBiome Therapeutics LLC Comapny Information
8.13.2 MicroBiome Therapeutics LLC Business Overview
8.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
8.13.5 MicroBiome Therapeutics LLC Recent Developments
8.14 Metabiomics
8.14.1 Metabiomics Comapny Information
8.14.2 Metabiomics Business Overview
8.14.3 Metabiomics Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.14.4 Metabiomics Microbiome Therapeutics Product Portfolio
8.14.5 Metabiomics Recent Developments
8.15 Ritter Pharmaceuticals
8.15.1 Ritter Pharmaceuticals Comapny Information
8.15.2 Ritter Pharmaceuticals Business Overview
8.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
8.15.5 Ritter Pharmaceuticals Recent Developments
8.16 Symberix
8.16.1 Symberix Comapny Information
8.16.2 Symberix Business Overview
8.16.3 Symberix Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.16.4 Symberix Microbiome Therapeutics Product Portfolio
8.16.5 Symberix Recent Developments
8.17 OpenBiome
8.17.1 OpenBiome Comapny Information
8.17.2 OpenBiome Business Overview
8.17.3 OpenBiome Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.17.4 OpenBiome Microbiome Therapeutics Product Portfolio
8.17.5 OpenBiome Recent Developments
8.18 Azitra
8.18.1 Azitra Comapny Information
8.18.2 Azitra Business Overview
8.18.3 Azitra Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.18.4 Azitra Microbiome Therapeutics Product Portfolio
8.18.5 Azitra Recent Developments
8.19 Symbiotix Biotherapies
8.19.1 Symbiotix Biotherapies Comapny Information
8.19.2 Symbiotix Biotherapies Business Overview
8.19.3 Symbiotix Biotherapies Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.19.4 Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
8.19.5 Symbiotix Biotherapies Recent Developments
8.20 Osel
8.20.1 Osel Comapny Information
8.20.2 Osel Business Overview
8.20.3 Osel Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.20.4 Osel Microbiome Therapeutics Product Portfolio
8.20.5 Osel Recent Developments
8.21 Metabogen
8.21.1 Metabogen Comapny Information
8.21.2 Metabogen Business Overview
8.21.3 Metabogen Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.21.4 Metabogen Microbiome Therapeutics Product Portfolio
8.21.5 Metabogen Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
1.1 Product Definition
1.2 Global Microbiome Therapeutics Market Size, 2019 VS 2023 VS 2030
1.3 Global Microbiome Therapeutics Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 MICROBIOME THERAPEUTICS MARKET DYNAMICS
2.1 Microbiome Therapeutics Industry Trends
2.2 Microbiome Therapeutics Industry Drivers
2.3 Microbiome Therapeutics Industry Opportunities and Challenges
2.4 Microbiome Therapeutics Industry Restraints
3 MICROBIOME THERAPEUTICS MARKET BY COMPANY
3.1 Global Microbiome Therapeutics Company Revenue Ranking in 2023
3.2 Global Microbiome Therapeutics Revenue by Company (2019-2024)
3.3 Global Microbiome Therapeutics Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Microbiome Therapeutics Company Manufacturing Base & Headquarters
3.5 Global Microbiome Therapeutics Company, Product Type & Application
3.6 Global Microbiome Therapeutics Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Microbiome Therapeutics Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Microbiome Therapeutics Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 MICROBIOME THERAPEUTICS MARKET BY TYPE
4.1 Microbiome Therapeutics Type Introduction
4.1.1 Upper GIT
4.1.2 Lower GIT
4.2 Global Microbiome Therapeutics Sales Value by Type
4.2.1 Global Microbiome Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Microbiome Therapeutics Sales Value by Type (2019-2030)
4.2.3 Global Microbiome Therapeutics Sales Value Share by Type (2019-2030)
5 MICROBIOME THERAPEUTICS MARKET BY APPLICATION
5.1 Microbiome Therapeutics Application Introduction
5.1.1 C. difficile Infection (CDI)
5.1.2 Inflammatory Bowel Disease (IBD)
5.1.3 Orphan Drug
5.1.4 Immuno-oncology
5.1.5 Others
5.2 Global Microbiome Therapeutics Sales Value by Application
5.2.1 Global Microbiome Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Microbiome Therapeutics Sales Value by Application (2019-2030)
5.2.3 Global Microbiome Therapeutics Sales Value Share by Application (2019-2030)
6 MICROBIOME THERAPEUTICS MARKET BY REGION
6.1 Global Microbiome Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Microbiome Therapeutics Sales Value by Region (2019-2030)
6.2.1 Global Microbiome Therapeutics Sales Value by Region: 2019-2024
6.2.2 Global Microbiome Therapeutics Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Microbiome Therapeutics Sales Value (2019-2030)
6.3.2 North America Microbiome Therapeutics Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Microbiome Therapeutics Sales Value (2019-2030)
6.4.2 Europe Microbiome Therapeutics Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Microbiome Therapeutics Sales Value (2019-2030)
6.5.2 Asia-Pacific Microbiome Therapeutics Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Microbiome Therapeutics Sales Value (2019-2030)
6.6.2 Latin America Microbiome Therapeutics Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Microbiome Therapeutics Sales Value (2019-2030)
6.7.2 Middle East & Africa Microbiome Therapeutics Sales Value Share by Country, 2023 VS 2030
7 MICROBIOME THERAPEUTICS MARKET BY COUNTRY
7.1 Global Microbiome Therapeutics Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Microbiome Therapeutics Sales Value by Country (2019-2030)
7.2.1 Global Microbiome Therapeutics Sales Value by Country (2019-2024)
7.2.2 Global Microbiome Therapeutics Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.3.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.4.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.5.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.6.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.7.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.8.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.9.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.10.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.11.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.12.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.13.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.14.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.15.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.16.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.17.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.18.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.19.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.20.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Microbiome Therapeutics Sales Value Growth Rate (2019-2030)
7.21.2 Global Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Seres Therapeutics
8.1.1 Seres Therapeutics Comapny Information
8.1.2 Seres Therapeutics Business Overview
8.1.3 Seres Therapeutics Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.1.4 Seres Therapeutics Microbiome Therapeutics Product Portfolio
8.1.5 Seres Therapeutics Recent Developments
8.2 Assembly Biosciences
8.2.1 Assembly Biosciences Comapny Information
8.2.2 Assembly Biosciences Business Overview
8.2.3 Assembly Biosciences Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.2.4 Assembly Biosciences Microbiome Therapeutics Product Portfolio
8.2.5 Assembly Biosciences Recent Developments
8.3 Synthetic Biologics
8.3.1 Synthetic Biologics Comapny Information
8.3.2 Synthetic Biologics Business Overview
8.3.3 Synthetic Biologics Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.3.4 Synthetic Biologics Microbiome Therapeutics Product Portfolio
8.3.5 Synthetic Biologics Recent Developments
8.4 Interxon
8.4.1 Interxon Comapny Information
8.4.2 Interxon Business Overview
8.4.3 Interxon Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.4.4 Interxon Microbiome Therapeutics Product Portfolio
8.4.5 Interxon Recent Developments
8.5 PureTech
8.5.1 PureTech Comapny Information
8.5.2 PureTech Business Overview
8.5.3 PureTech Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.5.4 PureTech Microbiome Therapeutics Product Portfolio
8.5.5 PureTech Recent Developments
8.6 Synlogic
8.6.1 Synlogic Comapny Information
8.6.2 Synlogic Business Overview
8.6.3 Synlogic Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.6.4 Synlogic Microbiome Therapeutics Product Portfolio
8.6.5 Synlogic Recent Developments
8.7 Enterome BioScience
8.7.1 Enterome BioScience Comapny Information
8.7.2 Enterome BioScience Business Overview
8.7.3 Enterome BioScience Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.7.4 Enterome BioScience Microbiome Therapeutics Product Portfolio
8.7.5 Enterome BioScience Recent Developments
8.8 4D Pharma
8.8.1 4D Pharma Comapny Information
8.8.2 4D Pharma Business Overview
8.8.3 4D Pharma Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.8.4 4D Pharma Microbiome Therapeutics Product Portfolio
8.8.5 4D Pharma Recent Developments
8.9 Second Genome
8.9.1 Second Genome Comapny Information
8.9.2 Second Genome Business Overview
8.9.3 Second Genome Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.9.4 Second Genome Microbiome Therapeutics Product Portfolio
8.9.5 Second Genome Recent Developments
8.10 AOBiome
8.10.1 AOBiome Comapny Information
8.10.2 AOBiome Business Overview
8.10.3 AOBiome Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.10.4 AOBiome Microbiome Therapeutics Product Portfolio
8.10.5 AOBiome Recent Developments
8.11 C3 Jian
8.11.1 C3 Jian Comapny Information
8.11.2 C3 Jian Business Overview
8.11.3 C3 Jian Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.11.4 C3 Jian Microbiome Therapeutics Product Portfolio
8.11.5 C3 Jian Recent Developments
8.12 Rebiotix
8.12.1 Rebiotix Comapny Information
8.12.2 Rebiotix Business Overview
8.12.3 Rebiotix Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.12.4 Rebiotix Microbiome Therapeutics Product Portfolio
8.12.5 Rebiotix Recent Developments
8.13 MicroBiome Therapeutics LLC
8.13.1 MicroBiome Therapeutics LLC Comapny Information
8.13.2 MicroBiome Therapeutics LLC Business Overview
8.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
8.13.5 MicroBiome Therapeutics LLC Recent Developments
8.14 Metabiomics
8.14.1 Metabiomics Comapny Information
8.14.2 Metabiomics Business Overview
8.14.3 Metabiomics Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.14.4 Metabiomics Microbiome Therapeutics Product Portfolio
8.14.5 Metabiomics Recent Developments
8.15 Ritter Pharmaceuticals
8.15.1 Ritter Pharmaceuticals Comapny Information
8.15.2 Ritter Pharmaceuticals Business Overview
8.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
8.15.5 Ritter Pharmaceuticals Recent Developments
8.16 Symberix
8.16.1 Symberix Comapny Information
8.16.2 Symberix Business Overview
8.16.3 Symberix Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.16.4 Symberix Microbiome Therapeutics Product Portfolio
8.16.5 Symberix Recent Developments
8.17 OpenBiome
8.17.1 OpenBiome Comapny Information
8.17.2 OpenBiome Business Overview
8.17.3 OpenBiome Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.17.4 OpenBiome Microbiome Therapeutics Product Portfolio
8.17.5 OpenBiome Recent Developments
8.18 Azitra
8.18.1 Azitra Comapny Information
8.18.2 Azitra Business Overview
8.18.3 Azitra Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.18.4 Azitra Microbiome Therapeutics Product Portfolio
8.18.5 Azitra Recent Developments
8.19 Symbiotix Biotherapies
8.19.1 Symbiotix Biotherapies Comapny Information
8.19.2 Symbiotix Biotherapies Business Overview
8.19.3 Symbiotix Biotherapies Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.19.4 Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
8.19.5 Symbiotix Biotherapies Recent Developments
8.20 Osel
8.20.1 Osel Comapny Information
8.20.2 Osel Business Overview
8.20.3 Osel Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.20.4 Osel Microbiome Therapeutics Product Portfolio
8.20.5 Osel Recent Developments
8.21 Metabogen
8.21.1 Metabogen Comapny Information
8.21.2 Metabogen Business Overview
8.21.3 Metabogen Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
8.21.4 Metabogen Microbiome Therapeutics Product Portfolio
8.21.5 Metabogen Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
LIST OF TABLES
Table 1. Microbiome Therapeutics Industry Trends
Table 2. Microbiome Therapeutics Industry Drivers
Table 3. Microbiome Therapeutics Industry Opportunities and Challenges
Table 4. Microbiome Therapeutics Industry Restraints
Table 5. Global Microbiome Therapeutics Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Microbiome Therapeutics Revenue Share by Company (2019-2024)
Table 7. Global Microbiome Therapeutics Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 8. Global Microbiome Therapeutics Key Company Manufacturing Base & Headquarters
Table 9. Global Microbiome Therapeutics Company, Product Type & Application
Table 10. Global Microbiome Therapeutics Company Commercialization Time
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Microbiome Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Major Companies of Upper GIT
Table 15. Major Companies of Lower GIT
Table 16. Global Microbiome Therapeutics Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Microbiome Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Microbiome Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Microbiome Therapeutics Sales Value Share by Type (2019-2024)
Table 20. Global Microbiome Therapeutics Sales Value Share by Type (2025-2030)
Table 21. Major Companies of C. difficile Infection (CDI)
Table 22. Major Companies of Inflammatory Bowel Disease (IBD)
Table 23. Major Companies of Orphan Drug
Table 24. Major Companies of Immuno-oncology
Table 25. Major Companies of Others
Table 26. Global Microbiome Therapeutics Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 27. Global Microbiome Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
Table 28. Global Microbiome Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
Table 29. Global Microbiome Therapeutics Sales Value Share by Application (2019-2024)
Table 30. Global Microbiome Therapeutics Sales Value Share by Application (2025-2030)
Table 31. Global Microbiome Therapeutics Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 32. Global Microbiome Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
Table 33. Global Microbiome Therapeutics Sales Value Share by Region (2019-2024)
Table 34. Global Microbiome Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
Table 35. Global Microbiome Therapeutics Sales Value Share by Region (2025-2030)
Table 36. Global Microbiome Therapeutics Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 37. Global Microbiome Therapeutics Sales Value by Country (2019-2024) & (US$ Million)
Table 38. Global Microbiome Therapeutics Sales Value Market Share by Country (2019-2024)
Table 39. Global Microbiome Therapeutics Sales Value by Country (2025-2030) & (US$ Million)
Table 40. Global Microbiome Therapeutics Sales Value Market Share by Country (2025-2030)
Table 41. Seres Therapeutics Company Information
Table 42. Seres Therapeutics Business Overview
Table 43. Seres Therapeutics Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 44. Seres Therapeutics Microbiome Therapeutics Product Portfolio
Table 45. Seres Therapeutics Recent Development
Table 46. Assembly Biosciences Company Information
Table 47. Assembly Biosciences Business Overview
Table 48. Assembly Biosciences Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 49. Assembly Biosciences Microbiome Therapeutics Product Portfolio
Table 50. Assembly Biosciences Recent Development
Table 51. Synthetic Biologics Company Information
Table 52. Synthetic Biologics Business Overview
Table 53. Synthetic Biologics Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 54. Synthetic Biologics Microbiome Therapeutics Product Portfolio
Table 55. Synthetic Biologics Recent Development
Table 56. Interxon Company Information
Table 57. Interxon Business Overview
Table 58. Interxon Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 59. Interxon Microbiome Therapeutics Product Portfolio
Table 60. Interxon Recent Development
Table 61. PureTech Company Information
Table 62. PureTech Business Overview
Table 63. PureTech Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 64. PureTech Microbiome Therapeutics Product Portfolio
Table 65. PureTech Recent Development
Table 66. Synlogic Company Information
Table 67. Synlogic Business Overview
Table 68. Synlogic Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 69. Synlogic Microbiome Therapeutics Product Portfolio
Table 70. Synlogic Recent Development
Table 71. Enterome BioScience Company Information
Table 72. Enterome BioScience Business Overview
Table 73. Enterome BioScience Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 74. Enterome BioScience Microbiome Therapeutics Product Portfolio
Table 75. Enterome BioScience Recent Development
Table 76. 4D Pharma Company Information
Table 77. 4D Pharma Business Overview
Table 78. 4D Pharma Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 79. 4D Pharma Microbiome Therapeutics Product Portfolio
Table 80. 4D Pharma Recent Development
Table 81. Second Genome Company Information
Table 82. Second Genome Business Overview
Table 83. Second Genome Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 84. Second Genome Microbiome Therapeutics Product Portfolio
Table 85. Second Genome Recent Development
Table 86. AOBiome Company Information
Table 87. AOBiome Business Overview
Table 88. AOBiome Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 89. AOBiome Microbiome Therapeutics Product Portfolio
Table 90. AOBiome Recent Development
Table 91. C3 Jian Company Information
Table 92. C3 Jian Business Overview
Table 93. C3 Jian Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. C3 Jian Microbiome Therapeutics Product Portfolio
Table 95. C3 Jian Recent Development
Table 96. Rebiotix Company Information
Table 97. Rebiotix Business Overview
Table 98. Rebiotix Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Rebiotix Microbiome Therapeutics Product Portfolio
Table 100. Rebiotix Recent Development
Table 101. MicroBiome Therapeutics LLC Company Information
Table 102. MicroBiome Therapeutics LLC Business Overview
Table 103. MicroBiome Therapeutics LLC Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
Table 105. MicroBiome Therapeutics LLC Recent Development
Table 106. Metabiomics Company Information
Table 107. Metabiomics Business Overview
Table 108. Metabiomics Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Metabiomics Microbiome Therapeutics Product Portfolio
Table 110. Metabiomics Recent Development
Table 111. Ritter Pharmaceuticals Company Information
Table 112. Ritter Pharmaceuticals Business Overview
Table 113. Ritter Pharmaceuticals Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
Table 115. Ritter Pharmaceuticals Recent Development
Table 116. Symberix Company Information
Table 117. Symberix Business Overview
Table 118. Symberix Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Symberix Microbiome Therapeutics Product Portfolio
Table 120. Symberix Recent Development
Table 121. OpenBiome Company Information
Table 122. OpenBiome Business Overview
Table 123. OpenBiome Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. OpenBiome Microbiome Therapeutics Product Portfolio
Table 125. OpenBiome Recent Development
Table 126. Azitra Company Information
Table 127. Azitra Business Overview
Table 128. Azitra Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Azitra Microbiome Therapeutics Product Portfolio
Table 130. Azitra Recent Development
Table 131. Symbiotix Biotherapies Company Information
Table 132. Symbiotix Biotherapies Business Overview
Table 133. Symbiotix Biotherapies Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
Table 135. Symbiotix Biotherapies Recent Development
Table 136. Osel Company Information
Table 137. Osel Business Overview
Table 138. Osel Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. Osel Microbiome Therapeutics Product Portfolio
Table 140. Osel Recent Development
Table 141. Metabogen Company Information
Table 142. Metabogen Business Overview
Table 143. Metabogen Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 144. Metabogen Microbiome Therapeutics Product Portfolio
Table 145. Metabogen Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Authors List of This Report
Table 148. Secondary Sources
Table 149. Primary Sources
Table 1. Microbiome Therapeutics Industry Trends
Table 2. Microbiome Therapeutics Industry Drivers
Table 3. Microbiome Therapeutics Industry Opportunities and Challenges
Table 4. Microbiome Therapeutics Industry Restraints
Table 5. Global Microbiome Therapeutics Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Microbiome Therapeutics Revenue Share by Company (2019-2024)
Table 7. Global Microbiome Therapeutics Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 8. Global Microbiome Therapeutics Key Company Manufacturing Base & Headquarters
Table 9. Global Microbiome Therapeutics Company, Product Type & Application
Table 10. Global Microbiome Therapeutics Company Commercialization Time
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Microbiome Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Major Companies of Upper GIT
Table 15. Major Companies of Lower GIT
Table 16. Global Microbiome Therapeutics Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Microbiome Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Microbiome Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Microbiome Therapeutics Sales Value Share by Type (2019-2024)
Table 20. Global Microbiome Therapeutics Sales Value Share by Type (2025-2030)
Table 21. Major Companies of C. difficile Infection (CDI)
Table 22. Major Companies of Inflammatory Bowel Disease (IBD)
Table 23. Major Companies of Orphan Drug
Table 24. Major Companies of Immuno-oncology
Table 25. Major Companies of Others
Table 26. Global Microbiome Therapeutics Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 27. Global Microbiome Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
Table 28. Global Microbiome Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
Table 29. Global Microbiome Therapeutics Sales Value Share by Application (2019-2024)
Table 30. Global Microbiome Therapeutics Sales Value Share by Application (2025-2030)
Table 31. Global Microbiome Therapeutics Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 32. Global Microbiome Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
Table 33. Global Microbiome Therapeutics Sales Value Share by Region (2019-2024)
Table 34. Global Microbiome Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
Table 35. Global Microbiome Therapeutics Sales Value Share by Region (2025-2030)
Table 36. Global Microbiome Therapeutics Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 37. Global Microbiome Therapeutics Sales Value by Country (2019-2024) & (US$ Million)
Table 38. Global Microbiome Therapeutics Sales Value Market Share by Country (2019-2024)
Table 39. Global Microbiome Therapeutics Sales Value by Country (2025-2030) & (US$ Million)
Table 40. Global Microbiome Therapeutics Sales Value Market Share by Country (2025-2030)
Table 41. Seres Therapeutics Company Information
Table 42. Seres Therapeutics Business Overview
Table 43. Seres Therapeutics Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 44. Seres Therapeutics Microbiome Therapeutics Product Portfolio
Table 45. Seres Therapeutics Recent Development
Table 46. Assembly Biosciences Company Information
Table 47. Assembly Biosciences Business Overview
Table 48. Assembly Biosciences Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 49. Assembly Biosciences Microbiome Therapeutics Product Portfolio
Table 50. Assembly Biosciences Recent Development
Table 51. Synthetic Biologics Company Information
Table 52. Synthetic Biologics Business Overview
Table 53. Synthetic Biologics Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 54. Synthetic Biologics Microbiome Therapeutics Product Portfolio
Table 55. Synthetic Biologics Recent Development
Table 56. Interxon Company Information
Table 57. Interxon Business Overview
Table 58. Interxon Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 59. Interxon Microbiome Therapeutics Product Portfolio
Table 60. Interxon Recent Development
Table 61. PureTech Company Information
Table 62. PureTech Business Overview
Table 63. PureTech Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 64. PureTech Microbiome Therapeutics Product Portfolio
Table 65. PureTech Recent Development
Table 66. Synlogic Company Information
Table 67. Synlogic Business Overview
Table 68. Synlogic Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 69. Synlogic Microbiome Therapeutics Product Portfolio
Table 70. Synlogic Recent Development
Table 71. Enterome BioScience Company Information
Table 72. Enterome BioScience Business Overview
Table 73. Enterome BioScience Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 74. Enterome BioScience Microbiome Therapeutics Product Portfolio
Table 75. Enterome BioScience Recent Development
Table 76. 4D Pharma Company Information
Table 77. 4D Pharma Business Overview
Table 78. 4D Pharma Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 79. 4D Pharma Microbiome Therapeutics Product Portfolio
Table 80. 4D Pharma Recent Development
Table 81. Second Genome Company Information
Table 82. Second Genome Business Overview
Table 83. Second Genome Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 84. Second Genome Microbiome Therapeutics Product Portfolio
Table 85. Second Genome Recent Development
Table 86. AOBiome Company Information
Table 87. AOBiome Business Overview
Table 88. AOBiome Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 89. AOBiome Microbiome Therapeutics Product Portfolio
Table 90. AOBiome Recent Development
Table 91. C3 Jian Company Information
Table 92. C3 Jian Business Overview
Table 93. C3 Jian Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. C3 Jian Microbiome Therapeutics Product Portfolio
Table 95. C3 Jian Recent Development
Table 96. Rebiotix Company Information
Table 97. Rebiotix Business Overview
Table 98. Rebiotix Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Rebiotix Microbiome Therapeutics Product Portfolio
Table 100. Rebiotix Recent Development
Table 101. MicroBiome Therapeutics LLC Company Information
Table 102. MicroBiome Therapeutics LLC Business Overview
Table 103. MicroBiome Therapeutics LLC Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
Table 105. MicroBiome Therapeutics LLC Recent Development
Table 106. Metabiomics Company Information
Table 107. Metabiomics Business Overview
Table 108. Metabiomics Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Metabiomics Microbiome Therapeutics Product Portfolio
Table 110. Metabiomics Recent Development
Table 111. Ritter Pharmaceuticals Company Information
Table 112. Ritter Pharmaceuticals Business Overview
Table 113. Ritter Pharmaceuticals Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
Table 115. Ritter Pharmaceuticals Recent Development
Table 116. Symberix Company Information
Table 117. Symberix Business Overview
Table 118. Symberix Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Symberix Microbiome Therapeutics Product Portfolio
Table 120. Symberix Recent Development
Table 121. OpenBiome Company Information
Table 122. OpenBiome Business Overview
Table 123. OpenBiome Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. OpenBiome Microbiome Therapeutics Product Portfolio
Table 125. OpenBiome Recent Development
Table 126. Azitra Company Information
Table 127. Azitra Business Overview
Table 128. Azitra Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Azitra Microbiome Therapeutics Product Portfolio
Table 130. Azitra Recent Development
Table 131. Symbiotix Biotherapies Company Information
Table 132. Symbiotix Biotherapies Business Overview
Table 133. Symbiotix Biotherapies Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
Table 135. Symbiotix Biotherapies Recent Development
Table 136. Osel Company Information
Table 137. Osel Business Overview
Table 138. Osel Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. Osel Microbiome Therapeutics Product Portfolio
Table 140. Osel Recent Development
Table 141. Metabogen Company Information
Table 142. Metabogen Business Overview
Table 143. Metabogen Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 144. Metabogen Microbiome Therapeutics Product Portfolio
Table 145. Metabogen Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Authors List of This Report
Table 148. Secondary Sources
Table 149. Primary Sources
LIST OF FIGURES
Figure 1. Microbiome Therapeutics Product Picture
Figure 2. Global Microbiome Therapeutics Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Microbiome Therapeutics Market Size (2019-2030) & (US$ Million)
Figure 4. Global Microbiome Therapeutics Company Revenue Ranking in 2023 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 7. Upper GIT Picture
Figure 8. Lower GIT Picture
Figure 9. Global Microbiome Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 10. Global Microbiome Therapeutics Sales Value Share 2019 VS 2023 VS 2030
Figure 11. Global Microbiome Therapeutics Sales Value Share by Type (2019-2030)
Figure 12. C. difficile Infection (CDI) Picture
Figure 13. Inflammatory Bowel Disease (IBD) Picture
Figure 14. Orphan Drug Picture
Figure 15. Immuno-oncology Picture
Figure 16. Others Picture
Figure 17. Global Microbiome Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Microbiome Therapeutics Sales Value Share 2019 VS 2023 VS 2030
Figure 19. Global Microbiome Therapeutics Sales Value Share by Application (2019-2030)
Figure 20. Global Microbiome Therapeutics Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 21. Global Microbiome Therapeutics Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 22. North America Microbiome Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 23. North America Microbiome Therapeutics Sales Value Share by Country (%), 2023 VS 2030
Figure 24. Europe Microbiome Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 25. Europe Microbiome Therapeutics Sales Value Share by Country (%), 2023 VS 2030
Figure 26. Asia-Pacific Microbiome Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 27. Asia-Pacific Microbiome Therapeutics Sales Value Share by Country (%), 2023 VS 2030
Figure 28. Latin America Microbiome Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 29. Latin America Microbiome Therapeutics Sales Value Share by Country (%), 2023 VS 2030
Figure 30. Middle East & Africa Microbiome Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 31. Middle East & Africa Microbiome Therapeutics Sales Value Share by Country (%), 2023 VS 2030
Figure 32. USA Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 33. USA Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 34. USA Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 35. Canada Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 36. Canada Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 37. Canada Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 38. Germany Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 39. Germany Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 40. Germany Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 41. France Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 42. France Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 43. France Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 44. U.K. Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 45. U.K. Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 46. U.K. Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 47. Italy Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 48. Italy Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 49. Italy Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 50. Netherlands Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 51. Netherlands Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 52. Netherlands Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 53. Nordic Countries Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 54. Nordic Countries Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 55. Nordic Countries Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 56. China Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 57. China Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 58. China Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 59. Japan Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 60. Japan Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 61. Japan Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 62. South Korea Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 63. South Korea Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 64. South Korea Microbiom
Figure 1. Microbiome Therapeutics Product Picture
Figure 2. Global Microbiome Therapeutics Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Microbiome Therapeutics Market Size (2019-2030) & (US$ Million)
Figure 4. Global Microbiome Therapeutics Company Revenue Ranking in 2023 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 7. Upper GIT Picture
Figure 8. Lower GIT Picture
Figure 9. Global Microbiome Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 10. Global Microbiome Therapeutics Sales Value Share 2019 VS 2023 VS 2030
Figure 11. Global Microbiome Therapeutics Sales Value Share by Type (2019-2030)
Figure 12. C. difficile Infection (CDI) Picture
Figure 13. Inflammatory Bowel Disease (IBD) Picture
Figure 14. Orphan Drug Picture
Figure 15. Immuno-oncology Picture
Figure 16. Others Picture
Figure 17. Global Microbiome Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Microbiome Therapeutics Sales Value Share 2019 VS 2023 VS 2030
Figure 19. Global Microbiome Therapeutics Sales Value Share by Application (2019-2030)
Figure 20. Global Microbiome Therapeutics Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 21. Global Microbiome Therapeutics Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 22. North America Microbiome Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 23. North America Microbiome Therapeutics Sales Value Share by Country (%), 2023 VS 2030
Figure 24. Europe Microbiome Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 25. Europe Microbiome Therapeutics Sales Value Share by Country (%), 2023 VS 2030
Figure 26. Asia-Pacific Microbiome Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 27. Asia-Pacific Microbiome Therapeutics Sales Value Share by Country (%), 2023 VS 2030
Figure 28. Latin America Microbiome Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 29. Latin America Microbiome Therapeutics Sales Value Share by Country (%), 2023 VS 2030
Figure 30. Middle East & Africa Microbiome Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 31. Middle East & Africa Microbiome Therapeutics Sales Value Share by Country (%), 2023 VS 2030
Figure 32. USA Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 33. USA Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 34. USA Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 35. Canada Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 36. Canada Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 37. Canada Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 38. Germany Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 39. Germany Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 40. Germany Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 41. France Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 42. France Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 43. France Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 44. U.K. Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 45. U.K. Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 46. U.K. Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 47. Italy Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 48. Italy Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 49. Italy Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 50. Netherlands Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 51. Netherlands Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 52. Netherlands Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 53. Nordic Countries Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 54. Nordic Countries Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 55. Nordic Countries Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 56. China Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 57. China Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 58. China Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 59. Japan Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 60. Japan Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 61. Japan Microbiome Therapeutics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 62. South Korea Microbiome Therapeutics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 63. South Korea Microbiome Therapeutics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 64. South Korea Microbiom
